Tu1283 PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL MOLECULE INHIBITOR TARGETING THE INTEGRIN α4β7 FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES (IBD)